Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04908514 · ClinicalTrials.gov registry record · Phase 2

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

A Phase 2 study, sponsored by Aldeyra Therapeutics.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target

NCT04908514: Completed Phase 2 study, sponsored by Aldeyra Therapeutics.

NCT04908514 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04908514, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target

Study Summary

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

Primary Outcome

The change from baseline for PASI score was assessed on a 0 to 72 scale (0 = none, 72 = maximum severity). Mixed model for repeated measures (MMRM) analysis was performed using change from baseline as the dependent variable, baseline as a covariate, and visit as a factor.

Interventions

  • DRUG ADX-629

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2021-05-07
Est. Completion 2022-01-21
Phase Phase 2
Aldeyra Therapeutics

26 total trials

What the finished NCT04908514 record still lists

NCT04908514 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which ADX-629 is the first listed.

NCT04908514 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04908514 about?

NCT04908514 is a clinical study titled "A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis". A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

What is the current status of trial NCT04908514?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-05-07. Estimated completion is 2022-01-21.

What interventions are being tested in trial NCT04908514?

The interventions under investigation include: ADX-629 (DRUG).

Who is sponsoring clinical trial NCT04908514?

This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04908514's enrollment target sits among peer trials

10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04908514, the US trial registry maintained by the National Library of Medicine. NCT04908514 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.